|
**Overview**: Differential Leukocyte Count Fluid Panel**Introduction**: The Differential Leukocyte Count Fluid Panel is a diagnostic tool designed to analyze fluid differential count using body fluid samples. In India, body fluid analysis (pleural, peritoneal, synovial, CSF) is crucial for distinguishing exudative (infection, malignancy) from transudative (heart failure, cirrhosis) effusions, with cell differential (neutrophils, lymphocytes, etc.) and biochemistry (protein, glucose) guiding diagnosis. High burden from underutilization in rural hospitals, limited cytology labs, delayed appropriate management leading to untreated TB pleurisy or malignancy. Per hematology practices aligned with ICMR guidelines, the test employs microscopy for cell count, differential, protein, glucose over 1-2 days with high accuracy, valuable for effusion workup. This diagnostic falls under fluid analysis and targets patients with unexplained fluid accumulation, addressing accurate detection to guide further tests (culture, ADA, cytology). With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise characterization and reducing complications. Its fluid-based approach ensures reliable cellular analysis.**Other Names**: DLC Fluid Pnl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Fluid differential standard; in India, key in TB and oncology workup.**Purpose**: The test assesses 8 parameters including neutrophils and cell count to guide fluid evaluation, classify exudate/transudate, inform management.**Test Parameters**: 1. Neutrophils, 2. Lymphocytes, 3. Monocytes, 4. Eosinophils, 5. Basophils, 6. Total Cell Count, 7. Protein, 8. Glucose.**Pretest Condition**: No fasting required; patients should report effusion symptoms.**Specimen**: 5 mL body fluid in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve cell integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate processing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for cytology).**Medical History**: Patients should provide details on effusion cause (TB, malignancy, heart failure), symptoms, prior taps.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed fluid abnormalities including infection or malignancy, benefits of early detection, and minimal discomfort from fluid collection.**Procedural Considerations**: The test involves sample processing using microscopy by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cellularity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal differential (e.g., lymphocytic in TB) indicates etiology, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Pulmonologists or physicians should be consulted for management.**Additional Supporting Tests**: Culture, ADA, cytology for confirmation.**Test Limitations**: May miss low-cellularity malignancy; comprehensive approach required.**References**: Indian Journal of Chest Diseases 2024, Fluid Analysis Studies India 2023. |
